SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2527From todays 8-K, On February 22, 2010 (the “Redemption Date”), Incyte CorporatiDaveyk-2/24/2010
25262009 worldwide in-market sales of Remicade were $5.3B. This figure comes from adDewDiligence_on_SI-2/23/2010
2525>> Remicade sales increased 14.8 percent to $4.3 billion in 2009 << scaram(o)uche-2/23/2010
2524WSJ, contains comment on INCY/Lilly deal <i>Poor reaction to AstraZeneca tom pope-2/23/2010
2523Found this about Dr Breedveld, who in 2008 was President of EULAR, and so a top quantman-2/19/2010
2522SS, thanks for your thoughtful comments. Much appreciated.quantman-2/18/2010
2521quantman, 1. i was just wondering whether the statement "that ratio in thesoftware salesperson-2/18/2010
2520Thanks, SS, as always for your excellent summary. 1. I agree with you that the quantman-2/18/2010
25192/18 cc notes here is the transcript from seeking alpha: seekingalpha.com hersoftware salesperson-2/18/2010
2518Blood. 2010 Feb 12. [Epub ahead of print] Efficacy of the JAK2 inhibitor INCB16scaram(o)uche-2/16/2010
2517Blood. 2010 Feb 3. [Epub ahead of print] Preclinical characterization of the sescaram(o)uche-2/10/2010
2516FMR files for 11.975% (14.3m). Haven't looked to see how that compares to tscaram(o)uche-2/10/2010
2515from j. birchenough's report today: VRTX has listed a phase 2 proof of concsoftware salesperson-2/9/2010
2514That is great news.Looks like management is bullish on this stock.Daveyk-1/29/2010
2513Incyte Announces Redemption of Its 3?% Convertible Senior Notes Due 2011 and Itsscaram(o)uche-1/28/2010
2512research on jak1/2 inhibitor incb16562 Neoplasia. 2010 Jan;12(1):28-38. INCB16software salesperson-1/27/2010
2511Website for the pivotal study: comfortstudy.comrkrw-1/24/2010
2510after hour blocks of 410K and 77K. Chart shows what looks like a ~ 500K block fscaram(o)uche-1/14/2010
2509three little nuggets, thus far..... prelim. survival data (vs. historical contscaram(o)uche-1/12/2010
2508Musings on the Actemra approval: siliconinvestor.com The note about Actemra, FDewDiligence_on_SI-1/9/2010
2507yet another biological approved, yet another target for Lilly to (rose-colored gscaram(o)uche-1/9/2010
2506<i>Do we expect this conversion price to serve as a quasi-floor to the traBiomaven-1/7/2010
2505Don't dare. I might be suspended for 'arryin'.tom pope-1/6/2010
2504I have no idea. We do know incyte swapped out a lot of this debt and also boughtrkrw-1/6/2010
2503Do we expect this conversion price to serve as a quasi-floor to the trading rangformer_pgs11/6/2010
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News